UPDATES ON BRAINCHILD-01,-02, AND-03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG

被引：0

作者：

Vitanza, Nicholas ^{[1
,2
]}

Gust, Juliane ^{[3
,4
]}

Wilson, Ashley ^{[5
]}

Huang, Wenjun ^{[5
]}

Perez, Francisco ^{[6
]}

Wright, Jason ^{[6
]}

Leary, Sarah ^{[1
,2
]}

Cole, Bonnie ^{[7
,8
]}

Albert, Catherine ^{[2
,9
]}

Pinto, Navin ^{[1
,2
]}

Orentas, Rimas ^{[1
,10
]}

Jensen, Michael ^{[1
]}

Park, Julie ^{[1
,2
]}

机构：

[1] Univ Washington, Seattle Childrens Hosp, Dept Pediat, Div Pediat Hematol Oncol, Seattle, WA 98195 USA

[2] Seattle Childrens Res Inst, Ctr Clin & Translat Res, Seattle, WA USA

[3] Univ Washington, Dept Neurol, Div Pediat Neurol, Seattle, WA 98195 USA

[4] Seattle Childrens Res Inst, Ctr Integrat Brain Res, Seattle, WA USA

[5] Seattle Childrens Res Inst, Immunotherapy Integrat Hub, Therapeut Innovat Core, Seattle, WA USA

[6] Univ Washington, Dept Pediat, Seattle Childrens Hosp, Div Radiol, Seattle, WA 98195 USA

[7] Seattle Childrens Hosp, Dept Labs, Seattle, WA USA

[8] Dept Pathol, Seattle, WA USA

[9] Univ Washington, Dept Pediat, Div Pediat Hematol Oncol, Seattle, WA 98195 USA

[10] Seattle Childrens Res Inst, Ben Towne Ctr Childhood Canc Res, Seattle, WA USA

来源：

NEURO-ONCOLOGY | 2020年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IMMU-03

引用

页码：360 / 360

页数：1

共 8 条

[1] INTERIM ANALYSIS FROM BRAINCHILD-03: SEATTLE CHILDREN'S LOCOREGIONAL B7-H3 CAR T CELL TRIAL FOR CHILDREN WITH RECURRENT CENTRAL NERVOUS SYSTEM TUMORS AND DIPG
Vitanza, Nicholas
Gust, Juliane
Wilson, Ashley
Huang, Wenjun
Chen, Dickson
Meechan, Michael
Biery, Matt
Myers, Carrie
Tahiri, Sophie
Crotty, Erin
Leary, Sarah
Cole, Bonnie
Browd, Samuel
Hauptman, Jason
Lee, Amy
Albert, Catherine
Pinto, Navin
Orentas, Rimas
Gardner, Rebecca
Jensen, Michael
Park, Julie
NEURO-ONCOLOGY, 2022, 24 : 83 - 83
[2] LOCOREGIONAL B7-H3-SPECIFIC CAR T CELLS FOR CHILDREN AND YOUNG ADULTS WITH DIPG: INTERIM REPORT OF BRAINCHILD-03 ARM C
Vitanza, Nicholas
Wilson, Ashley
Yokoyama, Jason
Johnson, Adam
Gust, Jule
Huang, Wenjun
Albert, Catherine
Pinto, Navin
Foster, Jessica
Orentas, Rimas
Paulovich, Amanda
Berens, Michael
Gardner, Rebecca
Jensen, Michael
Park, Julie
NEURO-ONCOLOGY, 2021, 23 : 56 - 56
[3] BrainChild-03: Intraventricular B7-H3 CAR T cells for recurrent/refractory central nervous system tumors and non-pontine diffuse midline glioma in children and young adults
Vitanza, Nicholas A.
Gust, Juliane
Ronsley, Rebecca
Wilson, Ashley L.
Huang, Wenjun
Seidel, Kristy
Albert, Catherine M.
Pinto, Navin
Orentas, Rimas J.
Gardner, Rebecca A.
Jensen, Michael C.
Park, Julie R.
CANCER RESEARCH, 2023, 83 (08)
[4] INTRAVENTRICULAR B7-H3 CAR T CELLS FOR DIFFUSE INTRINSIC PONTINE GLIOMA: SAFETY AND EFFICACY REPORT FROM THE COMPLETED PHASE 1 TRIAL BRAINCHILD-03
Vitanza, Nicholas A.
Ronsley, Rebecca
Huang, Wenjuan
Seidel, Kristy
Thomsen, Alison
Gust, Juliane
Hauptman, Jason
Choe, Michlle
Crotty, Erin
Leary, Sarah
Gustafson, Joshua A.
Gardner, Rebecca A.
Pattabhi, Sowmya
Wendler, Jason
Ho, On
Annesley, Colleen
Park, Julie R.
Jensen, Michael C.
NEURO-ONCOLOGY, 2024, 26
[5] STRIvE-02 Arm C: Phase 1 study of concurrent PD-1 inhibition with B7-H3 CAR T cell immunotherapy for recurrent/refractory pediatric solid tumors
Choe, Michelle
Taylor, Mallory
Wendler, Jason
Narayanaswamy, Prabha
Rawlings-Rhea, Stephanie
Seidel, Kristy
Huang, Wenjun
Pattabhi, Sowmya
Gamble, Danielle
Ho, On
Wilson, Ashley
Mgebroff, Stephanie
Brown, Christopher
Lindgren, Catherine
Annesley, Colleen
Gardner, Rebecca Alice
Jensen, Michael
Park, Julie R.
Albert, Catherine Michelle
Pinto, Navin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] PRECLINICAL EFFICACY OF MULTI-ANTIGEN (HER2/ EGFR806/B7-H3/IL13RA2) TARGETING QUAD-CAR T CELLS AGAINST DIFFUSE MIDLINE GLIOMA
Myers, Carrie
Timpanaro, Andrea
Song, Edward
Meechan, Michael
Chen, Alex
Biery, Matthew
Reid, Aquene
Gwiazda, Kamila
Baldwin, Michael
Gustafson, Joshua
Gardner, Rebecca
Jensen, Michael
Vitanza, Nicholas
NEURO-ONCOLOGY, 2023, 25
[7] STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
Pinto, Navin R.
Albert, Catherine Michelle
Taylor, Mallory
Wilson, Ashley
Rawlings-Rhea, Stephanie
Huang, Wenjun
Seidel, Kristy
Narayanaswany, Prabha
Wu, Vicky
Brown, Christopher
Nicholas, A.
Orentas, Vitanza Rimas
Gardner, Rebecca Alice
Jensen, Michael C.
Park, Julie R.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3ε conditional bispecific redirected activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors.
Richardson, Gary Edward
Kichenadasse, Ganessan
Zorko, Nicholas
Ma, Wen Wee
Chen, Huizi
Starks, David
Sutherland, Sarah
Kamasani, Sujana
Khot, Antari
Ma, Xin
Trepicchio, William L.
Zhang, Yefei
Ahern, Elizabeth Stephanie
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 →